SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs rally to fresh highs is drawing attention amid bullish analyst upgrades, including Goldmans Buy rating tied to sovereign AI demand and customized software opportunities. Bulls are celebrating the breakout and speculating about a short squeeze, while skeptics argue the valuation is stretched and expect a pullback.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Nasdaq-100 reentry and expected index-fund buying, alongside optimism about a planned NIH cancer-vaccine initiative and its partnered melanoma-vaccine results, are driving attention. Bulls see momentum in the oncology opportunity, while bears argue the rally is fueled by index flows and speculation rather than proven commercial returns.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is drawing attention around its share lockup expiration, as traders debate whether newly tradable shares are adding selling pressure after a sharp, volatile run. Bulls are holding for anticipated Anthropic IPO-related upside, while bears argue the funds premium to net asset value and increased share supply leave room for further weakness.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

DOTs sharp rebound from recent lows has prompted debate over whether it marks a genuine recovery or a short-lived bounce, with traders citing technical momentum and Polkadot upgrades while skeptics point to the tokens prolonged decline and weak demand.

Valero Energy Corp. engages in the manufacture and marketing of transportation fuels and other petrochemical products. It operates through the following business segments: Refining, Ethanol and Renewable Diesel. The Refining segment consists of refining operations, associated marketing activities, and logistics assets that support its refining operations. The Ethanol segment includes its ethanol operations, associated marketing activities, and logistics assets that support its ethanol operations. The Renewable Diesel covers the operations of Diamond Green Diesel Holdings LLC. The company was founded in 1980 and is headquartered in San Antonio, TX.

Valero Energy Corp.

Record-tight diesel markets and unusually wide refining crack spreads, driven by geopolitical supply disruptions, are the main focus behind Valeros rally and repeated highs. Traders remain divided: some see strong refining earnings supporting the shares, while others warn the rally is stretched and diesel-export-ban proposals or analyst downgrades could pressure margins.

Marathon Petroleum Corp. engages in the refining, marketing, and transportation of petroleum products. It operates through the Refining and Marketing, and Midstream segments. The Refining and Marketing segment includes refining crude oil and other feedstocks, purchasing ethanol, and refined products for resale and distribution of refined products. The Midstream segment refers to transportation, storing, distribution, and marketing of crude oil and refined products. The company was founded in 1887 and is headquartered in Findlay, OH.

Marathon Petroleum Corp

MPCs record-setting run is being linked to elevated diesel prices and wide refining margins amid tight refined-fuel supply, with a Mizuho price-target increase also drawing attention. Traders are upbeat about refiners profitability and momentum, while others warn the rally may be stretched and margins could ease.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRSP is drawing attention ahead of expected clinical updates: zugo-cel data in systemic sclerosis and CTX310 Phase 1b results. Traders see the readouts as potential catalysts, but many remain skeptical after the stocks prolonged range-bound trading.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentums CEO said its optical components are sold out through early 2029, with supply shortfalls expected as AI data-center demand outpaces capacity, prompting a rally and fresh highs. Traders are divided: bulls see sustained demand for AI networking optics, while skeptics argue capacity limits could constrain growth and that the stocks valuation is stretched.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRK is drawing attention amid a sharp rally, with traders pointing to Starknets privacy push through STRK20 and strkBTC, its Bitcoin DeFi plans, and its post-quantum security narrative. Bulls see these developments as differentiators, while skeptics remain concerned about token unlocks and the tokens weak longer-term performance.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflakes strong quarterly results and raised outlook, which traders connect to accelerating AI-driven platform demand, have fueled a sharp rally and breakout talk. Bullish momentum and software-sector rotation are tempered by concerns about the stocks rich valuation, ongoing unprofitability, and potential profit-taking.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer  

Rasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold.

TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses 

Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.

NTHI Heads into Wednesday with a Rare Biotech Convergence: Brain-Cancer Data, Tight Float, and Analyst Targets

DENVER, Colo. ( 247marketnews.com ) — NeOnc Technologies (NASDAQ:NTHI) is heading into Wednesday with the kind of setup that can put a clinical-stage biotech squarely on the market’s radar: a stock tr...

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer 

Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.

How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%

The average of price targets set by Wall Street analysts indicates a potential upside of 49.5% in Tango Therapeutics (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Tango Therapeutics Rides a New Precision Oncology Trend in 2026

TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and commercial potential.

Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?

Tango Therapeutics' strong 2026 rally reflects promising clinical progress, but its premium valuation puts upcoming study results at the center of the next move.

TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts

Tango Therapeutics enters a pivotal phase as vopimetostat drives its investment case, with 2026 clinical updates set to test its focused oncology pipeline.

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, Antoni Ribas and Barbara Weber in 2017 and is headquartered in Boston, MA.

Tango Therapeutics Inc

TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’

Equity

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$TNGX Still up almost 2000% in ~ 16 months. This, like many other biotechs up 100 - 2000% in the past 18 months have lots of room to retrace and still leave many with enormous gains. War, dollar, inflation, food crisis all going to get worse IMO. Lots of room below. Good luck.

LabPsycho

$TNGX The spotlight is on tango! Look the interest of RVMD, and the curiosity of JPMorgan

Filipe Pina

$TNGX Tango Therapeutics, Inc. (TNGX) has an affiliate officer, Jessica Newcomb, filing a notice to sell common stock under Rule 144. The filing covers up to 15,231 shares of Tango Therapeutics common stock to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $340,108.23 as of September 22, 2026. 
 
Not a good look!

Feed

News

Sentiment

Earnings

Fundamentals

Info

TNGX Tango Therapeutics Inc

Fundamentals

Latest TNGX News